medigraphic.com
ISSN 1561-3062 (Digital)

2016, Número 2

<< Anterior Siguiente >>

Revista Cubana de Obstetricia y Ginecología 2016; 42 (2)


Cardiomiopatía periparto

Pérez TJE, Román RPA, García SI, Sánchez RNM, Castillo AI, Peña BV

Idioma: Español
Referencias bibliográficas: 53
Paginas: 223-237
Archivo PDF: 137.99 Kb.


RESUMEN

La evolución normal del embarazo, parto o puerperio, puede verse afectada ocasionalmente por la aparición de insuficiencia cardiaca. La mayoría de las veces el origen del síndrome es la presencia de enfermedad cardiovascular previa (conocida o no), y la iatrogenia. El objetivo del trabajo fue presentar una revisión actualizada del concepto, epidemiología, mecanismos fisiopatológicos y estrategias de tratamiento de la cardiomiopatía periparto. Se realizó una revisión actualizada de la literatura internacional sobre el tema. Esta entidad se caracteriza por un síndrome de insuficiencia cardiaca por disfunción sistólica ventricular relacionada con el embarazo. Frecuentemente hace su aparición en el periparto, siendo el especialista en Obstetricia, u otro personal que asiste a la mujer gestante o puérpera quien a menudo tiene el primer contacto con la paciente. Aunque la etiología de la enfermedad es desconocida, nuevas teorías que involucran la predisposición genética, y su relación compleja con la hipófisis, placenta, cardiomiocito y células endoteliales, generan avances en el manejo específico de la enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Virchow R. Sitzing der Berliner Geburtshilflisher Gersellskhalt. l'influence réciproque de la grossesse et des maladies du Coeur. [Tesis]. Paris; 1880.

  2. Porak C. De l'influence réciproque de la grossesse et des maladies du Coeur. [Tesis]. Paris; 1880.

  3. Gouley BA, McMillan TM, Bellet S. Idiopathic myocardial degeneration associated with pregnancy and especially the puerperium. Am J Med Sci. 1937;19:185-99.

  4. Karaye, KM, Henein MY. Peripartum cardiomyopathy: A review article. Int J Cardio. 2013;164:33-8.

  5. Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopathy. Heart. 2011; 97:1970e1981. doi:10.1136/heartjnl-2011-300349.

  6. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation 1971;44:964-8.

  7. Pearson GD, Veille JC, Rahimtoola S. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183e8.

  8. Elliott P, Andersson B, Arbustini E. Classification of the cardiomyopathies: aposition statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270-6.

  9. Sliwa K, Hilfiker-Kleiner D, Petrie MC. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767-78.

  10. Elkayam U. Clinical Characteristics of Peripartum Cardiomyopathy in the United States: Diagnosis, Prognosis, and Management. JACC. 2011;58(7):659-70.

  11. Kao DP, Hsich E, Lindenfeld J. Characteristics, Adverse Events, and Racial Differences Among Delivering Mothers With Peripartum Cardiomyopathy. JACC:Heart Failure. 2013;1(5):409-16.

  12. Mielniczuk LM, Williams K, Davis DR, Tang AS, Lemery R, Green MS, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006 Jun. 15;97(12):1765-8.

  13. Givertz MM. Peripartum Cardiomyopathy. Circulation. 2013;127:e622-e626.

  14. Goland S. Differences in Clinical Profile of African-American Women With Peripartum Cardiomyopathy in the United States. J Cardiac Fail. 2013;19:214e218.

  15. Brar SS, Khan SS, Sandhu GK. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100(2):302-4.

  16. Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct. 1995;25:118-23.

  17. Sanderson JE, Adesanya CO, Anjorin FI, Parry EHO. Postpartum cardiac failureheart failure due to volume overload? Am Heart J. 1979;97:613-21.

  18. Goland S, Modi K, Bitar F. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009;15:645e50.

  19. Elkayam U, Akhter MW, Singh H. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005;111:2050e5.

  20. Laonigro I, Correale M, Di Biase M, Altomare E. Alcohol abuse and heart failure. Eur J Heart Fail. 2009;11:453-62.

  21. Maisch B, Richter A, Sandmöller A, Portig I, Pankuweit S. BMBF Heart Failure Network. Inflammatory dilated cardiomyopathy (DCMI). Herz. 2005;30:535-44.

  22. Habli M, O'Brien T, Nowack E. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gynecol. 2008;199:415.e1e5.

  23. Hibbard JU, Lindheimer M, Lang R. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol. 1999;94:311- 6.

  24. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an omnious diagnosis. Am J Obstet Gynecol. 1997;176:182-8.

  25. Safirstein JG, Ro AS, Grandhi S, Wang L, Fett JD, Staniloae C. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol. 2012;154(1):27-31.

  26. Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2008;10:861-8.

  27. Hu CL, Li YB, Zang JM, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart. 2007;93:488-90.

  28. Ntusi NBA, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol .2009;131:168-79.

  29. Warraich RS, Sliwa K, Damasceno A, et al. Impact of pregnancy related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J. 2005;150:263e9.

  30. Liu J, Wang Y, Chen M, Zhao W, Wang X, et al. The Correlation between Peripartum Cardiomyopathy and Autoantibodies against Cardiovascular Receptors. PLoS ONE. 2014;9(1):e86770.doi:10.1371.

  31. Fett JD, Sundstrom BJ, Ansari AA, Etta King M. Mother-daughter peripartum cardiomyopathy. Int J Cardiol. 2002;86:331-2.

  32. Baruteau AE, Leurent G, Schleich JM, Gervais R, Daubert JC, Mabo P. Can peripartum cardiomyopathy be familial? Int J Cardiol. 2009;137:183-5.

  33. Haghikia A. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 2013;108:366.

  34. Karaye KM, Henein MY. Peripartum cardiomyopathy: A review article. International Journal of Cardiology. 2013;164:33-8.

  35. Sliwa K, Forster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27:441e6.

  36. Fett JD, Ansari AA, SundstromJB, Combs GF. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int J Cardiol. 2002;86:311-6.

  37. Cenac A, Simonoff M, Moretto P, Djibo A. A low plasma selenium is a risk factor for peripartum cardiomyopathy. A comparative study in Sahelian Africa. Int J Cardiol. 1992;36:57-9.

  38. Hilfiker-Kleiner D. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3):589-600.

  39. Patten IS. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485(7398):333-8.

  40. Yang Y, Rodríguez JE, Kitsis RN. A microRNA links prolactin to peripartum cardiomyopathy. J Clin Invest. 2013;123(5):1925-7.

  41. Halkein J. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013;123(5):2143-54.

  42. Walena K. Circulating microparticles as indicators of peripartum cardiomyopathy. European Heart Journal. 2012;33:1469-79.

  43. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999;30:111-42.

  44. Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E, Horstman LL, Soriano AO, Zambrano JP, Ahn YS. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol. 2005;45:1467-71.

  45. Meziani F, Tesse A, David E, Martinez MC, Wangesteen R, Schneider F, Andriantsitohaina R. Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am J Pathol. 2006; 169:1473-83.

  46. Yancy CW. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2013 doi: 10.1016/ j.jacc.2013.05.019.

  47. Grupo de Trabajo de Diagnóstico y Tratamiento de la Insuficiencia Cardiaca Aguda y Crónica de la Sociedad Europea de Cardiología. Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Rev Esp Cardiol. 2012;65(10):938.e1-e59.

  48. Sliwa K, Blauwet L, Tibazarwa K. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof of concept pilot study. Circulation. 2010;121:1465-73.

  49. Habedank D, Kuhnle Y, Elgeti T, Dudenhausen JW, HaverkampW, Dietz R. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail. 2008;10:1149-51.

  50. Cooper LT, Mather PJ, Alexis JD, Pauly DF, Torre-Amione G, Wittstein IS, et al. Myocardial Recovery in Peripartum Cardiomyopathy: Prospective Comparison With Recent Onset Cardiomyopathy in Men and Nonperipartum Women. J Cardiac Fail. 2012;18:28-33.

  51. Habli M, O'Brien T, Nowack E, Khoury S, Barton JR, Sibai B. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gyenecol. 2008;199:415.e1-5.

  52. Elkayam U, Tummala PP, Rao K. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001;334:1567-71.

  53. Rasmusson KD, Budge D, Alharethi R. Long-term outcomes in patients with peripartum cardiomyopathy and no recovery of left ventricular function. J Card Fail. 2010;16:S97.




2020     |     www.medigraphic.com